Epigenetic inhibitors attenuate pathological gene expression in cardiomyocytes

Epigenetic modulators have been proposed as promising new drug targets to treat adverse remodeling in heart failure. Here, we evaluated the potential of 4 epigenetic drugs, including the pan-BRD (bromodomain-containing protein) inhibitor bromosporine, the BET (bromodomain and extraterminal) inhibitor JQ1, more…

BJP Themed Issue: Therapeutic targeting of the aldosterone–mineralocorticoid receptor signaling pathway

During the past few years enormous research activities substantially advanced our understanding of the molecular, cellular, and pathophysiological functions of the MR. The British Journal of Pharmacology now publishs a themed issue summarizing the current knowledge of the aldosterone-MR signaling more…

Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms

MR antagonists have proven to be highly efficient in patients with heart failure and reduced ejection fraction, and they are a cornerstone of contemporary therapy. In the past decade, a series of experimental studies using models with cell type–specific MRs uncovered the more…